4.4 Review

Quality of Life in Sarcopenia and Frailty

期刊

CALCIFIED TISSUE INTERNATIONAL
卷 93, 期 2, 页码 101-120

出版社

SPRINGER
DOI: 10.1007/s00223-013-9758-y

关键词

Age; Aging; Muscle weakness; Quality of life; Malnutrition

资金

  1. Novartis
  2. Servier
  3. Negma
  4. Lilly
  5. Wyeth
  6. Amgen
  7. Glaxo SmithKline
  8. Roche
  9. Merckle
  10. Nycomed
  11. NPS
  12. Theramex
  13. UCB
  14. Merck Sharp
  15. Dohme
  16. Rottapharm
  17. IBSA
  18. Genevrier
  19. Teijin
  20. Teva
  21. Ebewee Pharma
  22. Zodiac
  23. Analis
  24. Novo-Nordisk
  25. Nolver
  26. Bristol Myers Squibb
  27. Eli Lilly
  28. Dairy Management
  29. Abbott
  30. Pronutrim
  31. Cytokinetics
  32. Nestec
  33. Health Technology Assessment NHS R&D HTA Programme of the UK
  34. Merck Sharpe
  35. Fabre
  36. Nutraveris
  37. SMB
  38. Medical Research Council [U1475000001, MC_UP_A620_1015, MC_U147585819, MC_UU_12011/2, G0400491, MC_U147585824, MC_UP_A620_1014, U1475000002, MC_UU_12011/1] Funding Source: researchfish
  39. National Institute for Health Research [NF-SI-0508-10082] Funding Source: researchfish
  40. MRC [MC_U147585819, G0400491, MC_UP_A620_1015, MC_UU_12011/2] Funding Source: UKRI

向作者/读者索取更多资源

The reduced muscle mass and impaired muscle performance that define sarcopenia in older individuals are associated with increased risk of physical limitation and a variety of chronic diseases. They may also contribute to clinical frailty. A gradual erosion of quality of life (QoL) has been evidenced in these individuals, although much of this research has been done using generic QoL instruments, particularly the SF-36, which may not be ideal in older populations with significant comorbidities. This review and report of an expert meeting presents the current definitions of these geriatric syndromes (sarcopenia and frailty). It then briefly summarizes QoL concepts and specificities in older populations and examines the relevant domains of QoL and what is known concerning QoL decline with these conditions. It calls for a clearer definition of the construct of disability, argues that a disease-specific QoL instrument for sarcopenia/frailty would be an asset for future research, and discusses whether there are available and validated components that could be used to this end and whether the psychometric properties of these instruments are sufficiently tested. It calls also for an approach using utility weighting to provide some cost estimates and suggests that a time trade-off study could be appropriate.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据